Plasma proteins differentially expressed with itacitinib plus epacadostat or parsaclisib treatment
| Plasma protein | Log2 fold change in protein level* | |
| Treatment group A: itacitinib 300 mg plus epacadostat 300 mg (n=12) | ||
| NCR1 | Natural cytotoxicity triggering receptor 1 (CD335) | −0.52569 |
| IL2-RA | Interleukin 2 receptor alpha chain (CD25) | −0.46984 |
| TNFSF13B | TNFSF member 13B (BAFF or CD257) | −0.45461 |
| CYR61 | Cysteine-rich angiogenic inducer 61 | 0.464913 |
| FGF-19 | Fibroblast growth factor 19 | 1.133495 |
| GAL | Galanin | 1.134796 |
| Treatment groups B-1 and B-2: itacitinib 300 mg plus parsaclisib 10 mg (n=12) | ||
| CD160 | Natural killer cell receptor, Ig superfamily member | −1.12002 |
| CXCL13 | CXC motif chemokine ligand 13 | −0.93206 |
| FCER2 | Fc epsilon RII (CD23) | −0.84571 |
| TNFRSF9 | TNFRSF member 9 (CD137) | −0.79495 |
| XCL1 | C motif chemokine ligand 1 (lymphotactin) | −0.78599 |
| NCR1 | Natural cytotoxicity triggering receptor 1 (CD335) | −0.76039 |
| FASLG | Fas ligand (TNFSF6 or CD95L) | −0.74582 |
| SIGLEC6 | Sialic acid binding Ig-like lectin 6 | −0.64892 |
| IL12 | Interleukin 12 | −0.6411 |
| TRANCE† | TNF-related activation-induced cytokine | −0.63516 |
| CD5 | Lymphocyte antigen T1 | −0.62866 |
| FcRL2 | Fc receptor-like protein 2 | −0.6028 |
| TNFB | TNF-beta (TNFSF1 or lymphotoxin-alpha) | −0.60078 |
| IL-12B | Interleukin 12 subunit beta | −0.5857 |
| FcRL6 | Fc receptor-like protein 6 | −0.5821 |
| SIT1 | Signaling threshold-regulating transmembrane adapter 1 | −0.52955 |
| LAIR-2 | Leukocyte-associated immunoglobulin-like receptor 2 (CD306) | −0.50665 |
| TNFRSF4 | TNFRSF member 4 (OX40 receptor or CD134) | −0.4735 |
| LILRB4 | Leukocyte Ig-like receptor subfamily B member 4 | −0.43298 |
| TNFRSF13B | TNFRSF member 13B (CD267) | −0.42143 |
| MUC-16 | Mucin 16 | 0.408191 |
| ST3GAL1 | ST3 beta-galactoside alpha-2,3-sialyltransferase 1 | 0.425019 |
| REG4 | Regenerating islet-derived protein 4 | 0.428488 |
| SMOC2 | SPARC-related modular calcium-binding protein 2 | 0.437624 |
| Flt3L | FMS-like tyrosine kinase 3 ligand | 0.514995 |
| GAL | Galanin | 0.564124 |
| THPO | Thrombopoietin | 0.59239 |
*Baseline (C1D1) vs on-treatment (C2D1) samples were compared using a paired t-test, with changes considered significant at FDR p<0.05 and a log2 fold change >0.4 or <−0.4.
†Receptor activator of nuclear factor kappa-Β ligand (RANKL) or TNFSF11.
BAFF, B cell activating factor; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; CD, cluster of differentiation; FDR, false discovery rate; Ig, immunoglobulin; TNF, tumor necrosis factor; TNFRSF, tumor necrosis factor receptor superfamily; TNFSF, tumor necrosis factor ligand superfamily.